Literature DB >> 3409442

Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog.

J I Brodfuehrer1, T J Wilke, G Powis.   

Abstract

The pharmacokinetics and metabolism of sulfamic acid diester were studied in the beagle dog and mouse. Elimination of sulfamic acid diester from the plasma and whole blood following i.v. administration at a dose of 193 mg/m2 was best approximated by a three-compartment model in both species. The compound was relatively rapidly cleared from the plasma, with a plasma beta half-life of 2.3 h and 0.9 h and a gamma half-life of 16 h and 3 h in the dog and the mouse, respectively. Sulfamic acid diester was taken up by blood cells and only slowly eliminated with a whole blood gamma half-life of 42 h in the dog and 32 h in the mouse. When sulfamic acid diester was infused i.v. to mice at 15 mg/kg over 8 h, the clearance for the parent drug was 13.2 ml/min kg from the plasma and 3.3 ml/min kg from the whole blood. Urine collected from mouse and dog contained the parent drug and three metabolic/breakdown products, namely, sulfamic acid 1,7-heptanemonoyl ester, sulfamic acid 3-hydroxyl-1,7-heptanediyl ester, and an unidentified product. Excretion of unchanged drug and products in mouse urine over 8 h accounted for less than 16% of the dose of sulfamic acid diester. Sulfamic acid diester did not react with glutathione in buffer, whole blood, or 100,000 g rat liver cytosol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409442     DOI: 10.1007/bf00257308

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

2.  Degradation of busulfan in aqueous solution.

Authors:  M Hassan; H Ehrsson
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

3.  Role of metabolism and oxidation-reduction cycling in the cytotoxicity of antitumor quinoneimines and quinonediimines.

Authors:  G Powis; E M Hodnett; K S Santone; K L See; D C Melder
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

4.  4-Methanesulfonyloxybutanol: hydrolysis of busulfan.

Authors:  P W Feit; N Rastrup-Andersen
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

5.  Glutathione S-transferases (rat and human).

Authors:  W H Habig; W B Jakoby
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines.

Authors:  M C Alley; G Powis; P L Appel; K L Kooistra; M M Lieber
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Urinary metabolites of busulfan in the rat.

Authors:  M Hassan; H Ehrsson
Journal:  Drug Metab Dispos       Date:  1987 May-Jun       Impact factor: 3.922

8.  Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC 329680) and its stability in buffer, blood and plasma.

Authors:  J I Brodfuehrer; G Powis
Journal:  J Chromatogr       Date:  1988-06-03

9.  Metabolism of 14C-busulfan in isolated perfused rat liver.

Authors:  M Hassan; H Ehrsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

10.  ENZYME-STRUCTURE RELATIONSHIPS IN THE ENDOPLASMIC RETICULUM OF RAT LIVER : A Morphological and Biochemical Study.

Authors:  L Ernster; P Siekevitz; G E Palade
Journal:  J Cell Biol       Date:  1962-12-01       Impact factor: 10.539

View more
  2 in total

1.  Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.

Authors:  R A Larson; R B Geller; L Janisch; J Milton; L B Grochow; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.

Authors:  M V Marshall; K D Carey; D D Von Hoff; J G Kuhn
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.